Medically reviewed by a licensed healthcare professional. Last updated March 2026.
Key Takeaways
- Retatrutide is a triple hormone receptor agonist (GLP-1, GIP, and glucagon) being developed by Eli Lilly [1].
- Phase 2 data showed up to 24.2% body weight loss in 48 weeks — potentially faster and greater weight loss than current options [1].
- Phase 3 trials (TRIUMPH program) are underway with results expected in 2026-2027 [2].
- If approved, retatrutide would be the most potent anti-obesity medication available.
- It is NOT yet FDA-approved and cannot be prescribed. Current GLP-1 options remain the standard of care.
What Is Retatrutide?
Retatrutide (LY3437943) is an investigational medication being developed by Eli Lilly — the same company that makes tirzepatide (Zepbound/Mounjaro). While current GLP-1 medications target one or two hormone receptors, retatrutide targets three [1]:
- GLP-1 (glucagon-like peptide-1): Reduces appetite, slows gastric emptying — the same target as semaglutide
- GIP (glucose-dependent insulinotropic polypeptide): Enhances insulin secretion, improves fat metabolism — also targeted by tirzepatide
- Glucagon: Increases energy expenditure, promotes fat breakdown in the liver, raises metabolic rate
The addition of glucagon receptor activation is what makes retatrutide unique. While GLP-1 and GIP reduce calorie intake, glucagon increases calorie expenditure — attacking obesity from both sides simultaneously.
Phase 2 Trial Results
The Phase 2 trial results, published in the New England Journal of Medicine in 2023, were remarkable [1]:
Weight Loss at 48 Weeks
| Dose | Average Weight Loss | % Achieving ≥15% Loss |
|---|---|---|
| 1 mg | 8.7% | 30% |
| 4 mg | 17.1% | 58% |
| 8 mg | 22.8% | 75% |
| 12 mg | 24.2% | 83% |
| Placebo | 2.1% | 4% |
The highest dose (12 mg) produced 24.2% weight loss in just 48 weeks — compared to 14.9% for semaglutide at 68 weeks (STEP 1) and 22.5% for tirzepatide at 72 weeks (SURMOUNT-1) [3][4].
Key Observations
- Faster onset: Weight loss with retatrutide appeared to accelerate more quickly than with current GLP-1 medications
- Weight loss still ongoing at 48 weeks: The weight loss curves had not plateaued by the end of the trial, suggesting even greater results with longer treatment
- Dose-dependent response: Higher doses produced progressively more weight loss, with the 12 mg dose showing the strongest effect
How Does It Compare?
Retatrutide vs. Semaglutide (Wegovy)
| Factor | Retatrutide (Phase 2) | Semaglutide (Phase 3) |
|---|---|---|
| Mechanism | Triple agonist (GLP-1/GIP/glucagon) | Single agonist (GLP-1) |
| Average weight loss | 24.2% at 48 weeks | 14.9% at 68 weeks |
| Targets addressed | Appetite + metabolism + liver fat | Appetite primarily |
| CV outcomes data | None yet | SELECT trial (20% CV event reduction) |
| FDA status | Phase 3 trials | Approved (2021) |
Retatrutide vs. Tirzepatide (Zepbound)
| Factor | Retatrutide (Phase 2) | Tirzepatide (Phase 3) |
|---|---|---|
| Mechanism | Triple agonist (GLP-1/GIP/glucagon) | Dual agonist (GLP-1/GIP) |
| Average weight loss | 24.2% at 48 weeks | 22.5% at 72 weeks |
| Speed to results | Faster weight loss trajectory | Slightly slower |
| FDA status | Phase 3 trials | Approved (2023) |
Important caveat: Comparing Phase 2 and Phase 3 results directly is not scientifically rigorous. Phase 2 trials are smaller and may show more favorable results than Phase 3 confirmatory studies. We need the Phase 3 TRIUMPH data to make valid comparisons.
The TRIUMPH Clinical Trial Program
Eli Lilly has launched Phase 3 trials under the TRIUMPH program to confirm retatrutide's safety and efficacy [2]:
- TRIUMPH-1: Retatrutide vs. placebo in adults with obesity (without diabetes)
- TRIUMPH-2: Retatrutide in adults with obesity and type 2 diabetes
- TRIUMPH-3: Long-term safety and efficacy study
- TRIUMPH-4: Additional populations and endpoints
These trials will enroll thousands of participants and are expected to report results beginning in late 2026 or 2027.
Potential Advantages
Metabolic Rate Enhancement
The glucagon component is particularly exciting because it may address one of the biggest challenges with current weight loss approaches: metabolic adaptation.
When you lose weight, your body reduces its metabolic rate to conserve energy. This metabolic slowdown is a major driver of weight regain. Glucagon receptor activation increases energy expenditure, potentially counteracting this adaptation [1].
Liver Fat Reduction
The Phase 2 trial showed significant reductions in liver fat among participants, even at lower doses. This suggests retatrutide could be particularly beneficial for patients with non-alcoholic fatty liver disease (NAFLD/NASH), which affects an estimated 25-30% of adults with obesity [1].
Potentially Sustained Weight Loss
The combination of reduced calorie intake (GLP-1 + GIP) and increased calorie expenditure (glucagon) may create a more durable metabolic shift that's harder for the body to compensate for, potentially reducing weight regain after plateau.
Side Effects
Phase 2 data showed a side effect profile similar to existing GLP-1 medications [1]:
- Nausea: 25-47% (dose-dependent)
- Diarrhea: 16-33%
- Vomiting: 9-19%
- Constipation: 6-17%
- Decreased appetite: 9-22% (also an intended effect)
GI side effects were dose-dependent and most common during dose titration, consistent with the pattern seen in semaglutide and tirzepatide. No new or unexpected safety signals were identified, though the Phase 3 studies with larger populations will provide more comprehensive safety data.
When Will Retatrutide Be Available?
The realistic timeline:
| Milestone | Expected Timing |
|---|---|
| Phase 3 results reported | Late 2026 - 2027 |
| FDA submission | 2027 (if Phase 3 successful) |
| FDA review period | 6-12 months |
| Potential FDA approval | Late 2027 - 2028 |
| Widespread availability | 2028+ |
This timeline could shift. FDA priority review, manufacturing scale-up, and insurance coverage negotiations all affect when patients can actually access the medication.
What Should You Do Right Now?
Retatrutide is promising, but it's not available today and won't be for at least 1-2 years. In the meantime:
- Don't wait. If you meet the criteria for GLP-1 treatment, current medications (semaglutide, tirzepatide) are effective and available now. Losing weight today provides immediate health benefits.
- Current options are excellent. Semaglutide and tirzepatide produce clinically significant weight loss with proven safety profiles. They are not "inferior" — they are well-established treatments.
- Stay informed. As TRIUMPH trial results are published, we'll update our coverage. Bookmark our blog for the latest GLP-1 medication news.
Ready to start treatment with currently available medications? Find a GLP-1 clinic near you or explore telehealth options to begin your consultation today.
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you are experiencing a medical emergency, call 911.
Sources
- Jastreboff AM, et al. "Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial." New England Journal of Medicine. 2023;389:514-526.
- Eli Lilly. TRIUMPH Clinical Trial Program. ClinicalTrials.gov.
- Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." New England Journal of Medicine. 2021;384:989-1002.
- Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." New England Journal of Medicine. 2022;387:205-216.